Ben Doak is the Head of Innovative Treatments at NHS England and has worked for the NHS since 2005 in a number of roles supporting evidence-based patient care. With his team, Ben is responsible for ensuring that services are in place so that patients can benefit from licensed Advanced Therapy Medicinal Products (ATMPs) recommended by NICE (the National Institute of Health and Care Excellence) in the NHS in England.

Since commencing his current role in 2020, Ben has overseen the expansion of CAR-T services in England, as well supporting access to ATMPs such as Zolgensma for spinal muscular atrophy, Libmeldy for metachromatic leukodystrophy and Upstaza for AADC deficiency. He maintains an active interest in horizon scanning of ATMPs and other innovative treatments.